期刊文献+

人乳头瘤病毒治疗性疫苗综合疗法的研究现状与临床潜力

Research status and clinical potential of comprehemive therapy of the therapeutic vaccine for inmmn papillo.mavirus
原文传递
导出
摘要 近年来,人乳头瘤病毒(HPV)治疗性疫苗的研究一直处于非常热门的地位,不少研究已经进入临床试验。HPV是宫颈癌的主要诱因,除了肿瘤细胞逃逸免疫机制外,HPV本身也有其特殊的逃逸机制,因此单一有效的治疗性疫苗研发有其一定的难度。从研究趋势上看,HPV治疗性疫苗联合其他治疗方式的综合性治疗或许成为有效的最新的研究热点而被认为具有更高的临床应用潜力。此文就目前的联合HPV治疗性疫苗的综合治疗方法研究进展进行综述,同时展望了未来值得探索的方向。 In recent years, research on therapeutic vaccine for human papillomavirus (HI:'V)and its clinical trials have been one of hot areas. HPV is the major cause of cervical cancer, in addition to regular immune escape mechanisms of HPV induced tumor cells, HPV also has a special escape mechanisms, this brings more di^culties to the development of therapeutic vaccine. Therefore a comprehensive treatment may be more effective for HPV-induced cervical cancer, and this is considered as the focus of latest research with a higher potential for clinical application. The recent progress on comprehensive therapy studies of the HPV therapeutic vaccine and explores directions worthy of future investigation are summarized in this review.
出处 《国际流行病学传染病学杂志》 CAS 2011年第4期278-280,共3页 International Journal of Epidemiology and Infectious Disease
基金 :浙江省科技计划重大项目(2007C03001-1)
关键词 疫苗 人乳头状瘤病毒 综合治疗 Vaccines Human papiUomavims Comprehensive therapy
  • 相关文献

参考文献23

  • 1Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clln, 2005,55(2): 74-108.
  • 2Chen CH, Wang TL, Hung CF, et al. Boosting with recombinant vaccinia increames HPV-16 E7-speeific T cell precursor frequencies of HPV-16 E7-expreming DNA vaccines. Vaccine, 2000, 18 (19): 2015-2022.
  • 3Wlazlo AP, Deng H, Giles-Davis W, et al. DNA vaccines against the human papillomavims type 16 E6 or E7 oneoproteins. Cancer Gene Ther, 2004, 11(6): 457-464.
  • 4Rittich S, Duskova M, Mackova J, et al. Combined immunization with DNA and transduced tumor cells expressing mouse GM-CSF or IL-2. Oncol Rep, 2005, 13(2): 311-317.
  • 5Lin cr, Hung CF, luang J, et al. Boosting with recombinant vaccinla increases HPV-16 ET-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles. Mol Ther, 2003, 8(4): 559-566.
  • 6Mackova J, Stasikova J, Kutinova L, et al. Prime/boost immunotherapy of HPVl6-induced tumors with E7 protein delivered by Bordetella adenylate cyclase and modified vaccinia virus Ankara. Cancer Immunol Immunother, 2006, 55(1): 39-46.
  • 7Kast WM. VEEV replicen-besed vaccines used in heterologous prime boost strategies induce lifelong proration against prostate cancer and therapy of cervical cancer in mice and robust cell-mediated immunity in Rhesus macques. (2008-06-01) [20114)2-20]. http://services. bepress, com/eci/vaccine/41.
  • 8Smyth I.J, Van Pcelgeest MI, Davidson EJ, et al. Immunological responses in womon with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost FIPV-16 oncogene vaccination. Clin Cancer Res, 2004, 10(9) : 2954-2961.
  • 9Fiander AN, Tristram A J, Davidson El, et al. Prime-boost vaccina- tion strategy in women with high-grade, noncervical anogenital intmepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gyneeol Cancer,2006, 16(3) : 1075-1081.
  • 10Davidson EJ, Faulkner RL, Sehr P, et al. Effect d TA-CIN (HPV 16 L2E6E7) booster irranunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaecinia vires encoding HPV 16/18 E6E7). Vaccine, 2004, 22(21/22): 2722-2729.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部